Home / Intelligence / Blog / AI-Based Software Paige Prostate is Granted FDA Approval Through the De Novo Regulatory Pathway
Published September 27, 2021
Paige Prostate is the first artificial intelligence (AI)-based software designed to identify areas of concern (i.e., high likelihood of containing cancer) on a prostate biopsy image so they can be flagged for further review by a pathologist. The program is intended to be used as an adjunct tool to the review of digital scanner slide images from prostate biopsies.
The program was reviewed through the De Novo pathway, a regulatory pathway for low-to-moderate risk novel devices. The FDA authorization is based on clinical trial data which suggests improved detection of cancer on slide images by an average of 7.3% with Paige Prostate vs. unassisted examination by pathologists. The program also reduced the number of false-negatives by 70% and false-positives by 24%. This FDA authorization follows Paige AI receiving a CE mark for both its prostate software and its breast cancer product for use in the EU last year.
Paige’s co-founder and chief medical officer, David Klimstra, notes that Paige’s landmark FDA-approval and EU access “marks the beginning of a new era in the use of computer-assisted diagnostics for pathology.”
Written by Crystal Zhao and Kate Watkins
Related Intelligence
Webinars
Unlock the Potential of Generative AI in Life Sciences Insights and Operations
May 2, 2024 | 1:00 – 1:45 PM ET
Two additional sessions will be offered: May 3, 2024 | 15:00-15:45 CET – Europe/Berlin May 8, 2024 | 16:00-16:45 (UTC+8:00) – Asia/Shanghai Generative AI (GenAI) has created an opportunity to re-think and significantly improve how we work. Although far from replacing humans, GenAI has the potential to make pharma professionals far more effective and valuable […]
Sign Up Now
White Papers
What Is Keeping Community Oncology Providers Up at Night?
Community oncology practices are critical to the delivery of cancer care in the United States, treating about 80%, of patients. (~40% in community clinics and ~40% in community hospitals). Providing top-quality care in the community setting has unique challenges, including keeping pace with the accelerating innovation in cancer care (13 novel drugs and additional 67 […]
Read More
Case Studies
Early Adopter Identification Engine
In order to plan and efficiently utilize their sales and marketing efforts, a mid-sized biopharma client wanted to identify HCPs likely to adopt their drug in the early stage of launch
Read More